How we classify pet treatment evidence

The Pet Treatment Index uses two separate labels on every future Treatment Record: a regulatory-status label and an evidence-stage label. The first describes the official veterinary marketing or development status we could verify for a defined species and use. The second describes how directly the available evidence supports the clinical claim in the target species.

The labels are not a treatment recommendation, safety guarantee, quality score, or substitute for veterinary judgment.

Core rule: We never present rodent, cell, healthy-animal, or other-species data as clinical efficacy in pets.

Why two labels are necessary

Regulatory status and evidence answer different questions.

A treatment may be legally marketed for a specific veterinary use and still have limitations, warnings, uncertain long-term effects, or a patient population that differs from an individual pet. A treatment may also have early biological or animal research without any approved veterinary product or controlled clinical evidence in client-owned dogs or cats.

Combining those situations into a single “proven” or “promising” score hides the decision. The Index keeps them visible.

Regulatory-status labels

A status label always applies to a defined scope: product or treatment, species, indication, formulation, route, and date checked. It does not silently extend to another species, condition, dose, formulation, route, or compounded preparation.

FDA approved

Use this label when a current FDA record supports approval of the specific animal drug for the species and indication described on the page.

The record should identify the approved scope and link to the authoritative product or approval information. FDA approval does not mean a treatment is appropriate for every animal, free of adverse effects, superior to every alternative, or approved for a different use that happens to involve the same ingredient.

Where a veterinarian may lawfully use an approved drug outside the label under applicable rules, the Index still distinguishes the approved label from the extra-label clinical decision.

FDA conditionally approved

Use this label when the current FDA record shows conditional approval for the defined veterinary use.

Conditional approval is a distinct legal status, not full approval. It generally reflects a pathway in which FDA requirements for safety and manufacturing quality have been met and a reasonable expectation of effectiveness has been shown while the sponsor continues collecting the evidence required for full effectiveness approval, subject to the governing statutory limits and annual renewal requirements.

The record must say conditionally approved, identify the scope, and avoid shortening the label to “FDA approved” in a way that removes the distinction.

Indexed for a minor species

Use this label when the treatment appears in FDA’s Index of Legally Marketed Unapproved New Animal Drugs for Minor Species for the defined use.

Indexing can provide a legal marketing pathway for certain uses in eligible minor species, but an indexed product is not FDA approved. The record must preserve that distinction and identify the species and use shown in the Index.

This label should not be used for dogs or cats merely because a product is marketed online or discussed as a veterinary compound.

Investigational

Use this label when a treatment is in a formal veterinary research or development pathway and is not approved, conditionally approved, or indexed for routine marketing for the claimed use.

A registered trial, investigational exemption, company development program, regulatory milestone, or published protocol may support the label. “Investigational” does not mean effective, available for purchase, or appropriate outside the authorized research setting.

The record should identify the actual stage and source rather than treating every product called “in development” as equally advanced.

Compounded or otherwise unapproved

Use this label when the veterinary product or preparation being discussed is not FDA approved for the claimed use and is compounded or otherwise marketed without approval.

Compounding can have a legitimate clinical role under veterinary oversight and applicable federal and state requirements. It does not convert the preparation into an FDA-approved animal drug. FDA guidance describing circumstances in which the agency intends to exercise enforcement discretion is not an approval, guarantee, or blanket authorization for every compound, seller, claim, or use.

The page must distinguish:

• an approved finished animal drug;
• extra-label use of an approved drug;
• a compounded preparation made from an approved drug;
• a preparation compounded from a bulk drug substance;
• and an online product marketed without a verified veterinary pathway.

Where the legal or regulatory facts are complex, the Index describes the official source and avoids a broader legal conclusion than the source supports.

No established veterinary marketing status located

Use this label when the Editorial Desk could not locate a current FDA approval, conditional approval, indexing record, or other established veterinary marketing status for the claimed species and use.

This is a finding about the official records checked, not a declaration that every possible use or possession is unlawful. The page must state what was searched, the scope of the claim, and the date checked.

Marketing language such as “research use,” “for laboratory use,” “wellness,” “supplement,” “peptide,” “natural,” or “veterinary grade” does not establish an approved veterinary status.

Evidence-stage labels

The evidence stage describes the most decision-relevant body of evidence for the page’s defined claim. It is not a mathematical score. Evidence within one stage can vary substantially in quality, relevance, size, duration, bias, and outcome.

1. FDA-reviewed target-species evidence

Use when the defined veterinary use is supported by target-species evidence reviewed through an FDA approval or conditional-approval process.

The record should still report:

• the approved or conditionally approved population and indication;
• the pivotal study design and comparator where available;
• sample size;
• primary outcome;
• duration;
• important exclusions;
• safety findings;
• and the difference between the official label and broader marketing claims.

This stage is not shorthand for “best for every pet.”

2. Multiple controlled target-species studies

Use when more than one relevant controlled clinical study in the target species supports the defined claim, but the evidence is not being classified through the FDA-reviewed stage above.

The studies should involve the relevant condition or patient population—not merely healthy animals—and use a design capable of comparing outcomes. The record must note important differences among formulations, doses, populations, outcomes, and sponsor involvement.

Publication count alone does not qualify a treatment. Multiple papers from the same small dataset do not automatically become multiple independent studies.

3. Limited target-species clinical evidence

Use when clinical evidence exists in the target species but is preliminary, small, uncontrolled, observational, retrospective, short, narrowly selected, or otherwise insufficient to support a stronger stage.

Examples may include:

• a small pilot study;
• a case series;
• a retrospective chart review;
• an open-label study without a meaningful comparator;
• or one controlled study with material limitations.

The record should explain exactly why the evidence is limited rather than using “more research is needed” as a vague disclaimer.

4. Preclinical or other-species evidence

Use when the material supporting the claim is primarily:

• cell or tissue research;
• laboratory or mechanistic work;
• rodent research;
• another animal species;
• healthy-animal pharmacokinetic, exposure, or toxicity work;
• or a disease model that does not establish clinical efficacy in real target-species patients.

This evidence can be scientifically meaningful. It can support a mechanism, a safety question, a dose-selection hypothesis, or further study. It cannot be presented as proof that the treatment produces a clinical benefit in dogs or cats.

The record must name the species and study type every time the evidence is summarized.

5. Anecdotal or marketing claims

Use when the claim is supported mainly by testimonials, clinician impressions without a reported study, influencer or seller statements, owner reports, promotional white papers without adequate methods, or repeated marketing claims.

Anecdotes may identify questions, side effects, access patterns, or outcomes worth studying. They cannot establish incidence, causation, efficacy, comparative benefit, or general safety.

The volume or confidence of testimonials does not move a treatment into a stronger evidence stage.

6. No meaningful evidence located

Use when the Editorial Desk could not locate meaningful evidence that addresses the defined clinical claim after searching the appropriate primary literature and official sources.

This does not prove that the treatment can never work. It means the page cannot responsibly describe the claimed benefit as evidence-supported on the date checked.

The record should state the search scope and avoid turning absence of located evidence into an unsupported declaration of harm or fraud.

How a stage is assigned

The Editorial Desk evaluates:

• species;
• clinical versus laboratory setting;
• actual patient condition;
• formulation and route;
• study design and comparator;
• allocation and blinding where reported;
• sample size and attrition;
• outcome definition;
• follow-up duration;
• consistency across studies;
• statistical and clinical relevance;
• sponsor, author, and publication conflicts;
• applicability to the marketed claim;
• and important missing data.

The highest-sounding study does not automatically control. The label should reflect the body of evidence most relevant to the claim, with conflicting or weaker findings visible.

Evidence is claim-specific

One treatment can have different evidence stages for different claims.

A product may have strong evidence for one approved indication and limited evidence for a different condition. A compound may have target-species pharmacokinetic data but no target-species clinical efficacy data. A procedure may have evidence for short-term pain outcomes but uncertainty about long-term function.

The page must not borrow certainty from one claim and apply it to another.

Safety receives its own analysis

The evidence stage primarily describes support for the claimed benefit. Safety is analyzed separately using:

• official label warnings and contraindications;
• pivotal and post-market evidence;
• adverse-event and safety communications;
• recalls and quality notices;
• duration and population limits;
• drug interactions or monitoring described by authoritative sources;
• and gaps in long-term or high-risk-patient evidence.

A lack of reported adverse events in a small or short study is not proof of safety. A safety signal is not automatically proof of causation. The record should state what the source can and cannot establish.

Conflicts and sponsor involvement

Industry funding does not automatically invalidate a study, and independent publication does not automatically make a study reliable. The Index reports material sponsor and author conflicts where available and evaluates the methods and applicability of the evidence.

When most evidence comes from one sponsor, one research group, one formulation, or one unpublished regulatory package, that concentration is a limitation worth stating.

What the framework does not do

The evidence framework does not:

• diagnose a pet;
• rank treatments by a universal score;
• calculate personalized benefit or risk;
• convert absence of evidence into proof of no effect;
• convert biological plausibility into clinical proof;
• guarantee the completeness of published literature;
• replace a veterinarian’s examination or judgment;
• or determine whether a particular treatment is legal in every circumstance or state.

Review and version status

Framework version: 1.0
Published: 2026-08-17
Last reviewed: 2026-08-17
Independent veterinary review: not yet completed. This page will name the reviewer, credential, scope, and review date if and when that review occurs.

Primary reference systems

• Animal Drugs @ FDA
• FDA Green Book
• How FDA approves animal drugs
• FDA conditional approval explained
• FDA Index for minor species
• FDA unapproved animal drugs
• FDA Guidance for Industry #256
• PubMed